Stefan Sjöberg

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY. 2026;44:100440
Body weight and waist circumference are differentially associated with the response to L-thyroxine treatment in primary hypothyroidism
Funkquist A; Sjoberg S; Zetterberg H; Bergman S; Rosvall J; Bjellerup P; Svensson J
Article: HELIYON. 2024;10(8):e29498
Mixed methods study on the feasibility of implementing periodic continuous glucose monitoring among individuals with type 2 diabetes mellitus in a primary care setting
Johansson U-B; Gleissman SA; Liden MK; Wickman M; Gustafsson B; Sjoberg S
Article: JOURNAL OF NEUROENDOCRINOLOGY. 2023;35(5):e13272
Higher CSF/serum free-T4 ratio is associated with improvement of quality of life during treatment with L-thyroxine
Funkquist A; Wandt B; Blennow K; Zetterberg H; Svensson J; Bjellerup P; Freund-Levi Y; Sjoberg S
Journal article: JOURNAL OF MEDICAL ECONOMICS. 2020;23(11):1311-1320
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
Jendle J; Ericsson A; Ekman B; Sjoberg S; Gundgaard J; da Rocha Fernandes J; Mardby A-C; Hunt B; Malkin SJP; Thunander M
Article: JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY. 2020;19:100218
Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism - A pilot study
Funkquist A; Bengtsson A; Johansson PM; Svensson J; Bjellerup P; Blennow K; Wandt B; Sjoberg S
Article: DIABETES THERAPY. 2019;10(6):2115-2130
Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
Sofizadeh S; Imberg H; Olafsdottir AF; Ekelund M; Dahlqvist S; Hirsch I; Filipsson K; Ahren B; Sjoberg S; Tuomilehto J; Lind M
Journal article: VALUE IN HEALTH. 2019;22:s575-s576
PDB23 SWITCHING TO INSULIN DEGLUDEC IS A COST-SAVING THERAPY FOR PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE SWEDISH SETTING BASED ON REAL WORLD DATA
Jendle J; Thunander M; Ekman B; Sjöberg S; Ericsson Å; da Rocha Fernandes J; Mårdby AC; Malkin SJP; Hunt B
Article: OBESITY SCIENCE & PRACTICE. 2019;5(2):130-140
Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5)
Ahmadi SS; Filipsson K; Dimenaes H; Isaksson SS; Imberg H; Sjoeberg S; Ahren B; Dahlqvist S; Gustafsson T; Tuomilehto J; Hirsch IB; Lind M
Article: BMJ-BRITISH MEDICAL JOURNAL. 2015;351:h5364
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahren B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark B-O; Sjoberg S; Pehrsson N-G
Article: JOURNAL OF LIPID RESEARCH. 2014;55(11):2408-2415
Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
Bonde Y; Breuer O; Luetjohann D; Sjoberg S; Angelin B; Rudling M
Article: EUROPEAN ENDOCRINOLOGY. 2013;9(1):37-39
Short-term Withdrawal of Levothyroxine, Induced Increase of Thyroid-stimulating Hormone and an Increase Ratio of Triiodothyronine to Thyroxine.
Carlwe M; Schaffer T; Sjöberg S
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2011;71(1):63-67
L-thyroxine treatment in primary hypothyroidism does not increase the content of free triiodothyronine in cerebrospinal fluid: A pilot study
Sjoberg S; Eriksson M; Werner S; Bjellerup P; Nordin C
Article: AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 2007;292(3):E709-E714
Lactate release from adipose tissue and skeletal muscle in vivo: defective insulin regulation in insulin-resistant obese women
Qvisth V; Hagstrom-Toft E; Sjoberg MS; Bolinder J
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2004;89(9):4693-4700
Combined hyperinsulinemia and hyperglycemia, but not hyperinsulinemia alone, suppress human skeletal muscle lipolytic activity in vivo
Qvisth V; Hagström-Toft E; Enoksson S; Sherwin RS; Sjöberg S; Bolinder J
Article: APPETITE. 2003;41(2):213-214
Changes in cerebrospinal fluid signalling substances and appetite scores following 48 h fast in healthy volunteers
Arner P; Sjöberg S; Nordin C; Eriksson M
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13(5):333-335
CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype
Nordin C; Dahl ML; Eklundh T; Eriksson M; Sjöberg S
Journal article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2003;23(2):461-467
Introductory experiments on ligand liposomes as delivery agents for boron neutron capture therapy.
Bohl Kullberg E; Carlsson J; Edwards K; Capala J; Sjöberg S; Gedda L
Journal article: JOURNAL OF ORGANOMETALLIC CHEMISTRY. 2003;680(1-2):188-192
High yield [125I]iodide-labeling of iodinated carboranes by palladium-catalyzed isotopic exchange
Winberg KJ; Barberà G; Eriksson L; Teixidor F; Tolmachev V; Viñas C; Sjöberg S
Article: JOURNAL OF INTERNAL MEDICINE. 2002;252(4):342-351
Residual insulin secretion is not coupled to a maintained glucagon response to hypoglycaemia in long-term type 1 diabetes
Sjöberg S; Ahrén B; Bolinder J
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2002;12:410-411
CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype
Nordin C; Dahl ML; Eklundh T; Eriksson M; Sjöberg S
Visa fler

Alla övriga publikationer

Conference publication: VALUE IN HEALTH. 2019;22:S575-S576
SWITCHING TO INSULIN DEGLUDEC IS A COST-SAVING THERAPY FOR PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE SWEDISH SETTING BASED ON REAL WORLD DATA
Jendle J; Thunander M; Ekman B; Sjoberg S; Ericsson A; Fernandes DRJ; Mardby AC; Malkin SJP; Hunt B
Conference publication: DIABETOLOGIA. 2019;62:S436
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes in a Swedish setting
Jendle JH; Thunander M; Sjoberg S; Ekman B; Mardby A-C; Fernandes JDR; Gundgaard J; Ericsson A
Conference publication: DIABETOLOGIA. 2015;58:S37
A randomised double-blind trial of liraglutide to control HbA_1c in subjects with type 2 diabetes treated with multiple daily insulin injections (MDILiraglutide trial)
Lind M; Hirsch I; Tuomilehto J; Dahlqvist S; Ahren B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark B-O; Sjoberg S; Pehrsson N-G
Letter: JOURNAL OF INTERNAL MEDICINE. 2005;257(3):313-314
Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'
Eriksson M; Angelin B; Sjöberg S
Letter: DIABETOLOGIA. 2002;45(7):1043-1044
Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients
Bolinder J; Sjöberg S; Persson A; Ahrén B; Sundkvist G
Review: LAKARTIDNINGEN. 1999;96(5):464-465
[Increased level of TSH can be a sign of adrenal cortex failure. Not necessarily thyroid gland disease].
Sjöberg S; Werner S
Book chapter: CANCER NEUTRON CAPTURE THERAPY. 1996;p. 131-136
Asymmetric Synthesis of o- and p-Carboranyl Amino Acids
Malmquist J; Carlsson J; Markides KE; Pettersson P; Olsson P; Sunnerheim-Sjöberg K; Sjöberg S
Book chapter: CANCER NEUTRON CAPTURE THERAPY. 1996;p. 49-56
Boron Neutron Capture Therapy Against Tumor Cells with Overexpression of the EGF-Receptor
Carlsson J; Gedda L; Grönvik C; Hartman T; Lindström A; Lundqvist H; Lövqvist A; Malmqvist J; Olsson P; Pontén J; Sjöberg S; Sjöström A; Stenerlöw B; Tilly N; Essand M; Tjarks W; Westermark B
Conference publication: DIABETOLOGIA. 1988;31(7):A543
ABNORMALITIES IN THE BINDING OF CIRCULATING INSULIN-LIKE GROWTH FACTOR-I TO THE CARRIER PROTEINS IN PROLIFERATIVE DIABETIC-RETINOPATHY
SJOBERG S; ARNER P; SKOTTNER A; GJOTTERBERG M
Conference publication: ACTA ENDOCRINOLOGICA. 1987;115:51
AN ASSOCIATION BETWEEN EARLY MICROANGIOPATHIC LESIONS, LACK OF INSULIN-SECRETION AND HLA DR 3/4, 3/X, 4/X PHENOTYPES IN LONG-TERM TYPE-1 DIABETES-MELLITUS
SJOBERG S; MOLLER E; OSTMAN J
Conference publication: ACTA ENDOCRINOLOGICA. 1985;110:91
RESIDUAL INSULIN PRODUCTION IN LONG-TERM TYPE-I DIABETES IS NOT RELATED TO MORE FAVORABLE LIPOPROTEIN PROFILES
SJOBERG S; GUNNARSSON R; ROSSNER S; OSTMAN J

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI